Meeting NewsVideo

VIDEO: New trials expand treatment options for diabetes, CVD

LOS ANGELES — In this video exclusive, Robert P. Giugliano, MD, SM, FACC, FAHA, clinical cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, presents an overview of recent trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group that advance the understanding of new therapies for diabetes, cardiovascular disease and beyond.

Giugliano, senior investigator with the TIMI Study Group, highlights a subgroup analysis of ENGAGE AF-TIMI 48, which compared the nonvitamin K antagonist oral anticoagulant edoxaban (Savaysa, Daiichi Sankyo) vs. warfarin in patients with and without diabetes; CAMELLIA-TIMI 61, which evaluated the weight-loss drug lorcaserin (Belviq, Eisai) vs. placebo in patients with diabetes and CVD; DECLARE-TIMI 58, which looked at the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) in patients with diabetes and CV risk; and the FOURIER and VESALIUS-CV trials of the PCSK9 inhibitor evolocumab (Repatha, Amgen) in various populations.

Watch the video for more.

LOS ANGELES — In this video exclusive, Robert P. Giugliano, MD, SM, FACC, FAHA, clinical cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, presents an overview of recent trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group that advance the understanding of new therapies for diabetes, cardiovascular disease and beyond.

Giugliano, senior investigator with the TIMI Study Group, highlights a subgroup analysis of ENGAGE AF-TIMI 48, which compared the nonvitamin K antagonist oral anticoagulant edoxaban (Savaysa, Daiichi Sankyo) vs. warfarin in patients with and without diabetes; CAMELLIA-TIMI 61, which evaluated the weight-loss drug lorcaserin (Belviq, Eisai) vs. placebo in patients with diabetes and CVD; DECLARE-TIMI 58, which looked at the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) in patients with diabetes and CV risk; and the FOURIER and VESALIUS-CV trials of the PCSK9 inhibitor evolocumab (Repatha, Amgen) in various populations.

Watch the video for more.

    See more from World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease